Andreasen P B, Danö P, Kirk H, Greisen G
Scand J Gastroenterol. 1977;12(5):531-5. doi: 10.3109/00365527709181330.
Seventeen patients with intestinal shunt for obesity and 11 control patients were given 15 mg phenazone per kg perorally to estimate the rate of absorption and hepatic metabolism of phenazone. The rate of absorption and the plasma clearance of phenazone as well as the 4-hydroxyphenazone excretion in the urine did not differ in the patients with intestinal shunt after the weight had stabilized. Thus, drug absorption and hepatic drug metabolizing capacity appear to be unaffected 12--57 months after intestinal shunting.
对17例接受肠道分流术治疗肥胖症的患者和11例对照患者口服非那宗,剂量为每千克体重15毫克,以评估非那宗的吸收速率和肝脏代谢情况。在体重稳定后,接受肠道分流术的患者中非那宗的吸收速率、血浆清除率以及尿中4-羟基非那宗的排泄量并无差异。因此,肠道分流术后12至57个月,药物吸收和肝脏药物代谢能力似乎未受影响。